Structural properties of fluids interacting via piece-wise constant potentials with a hard core

The structural properties of fluids whose molecules interact via potentials with a hard core plus two piece-wise constant sections of different widths and heights are presented. These follow from the more general development previously introduced for potentials with a hard core plus $n$ piece-wise constant sections [Condens. Matter Phys. {\bf 15}, 23602 (2012)] in which use was made of a semi-analytic rational-function approximation method. The results of illustrative cases comprising eight different combinations of wells and shoulders are compared both with simulation data and with those that follow from the numerical solution of the Percus-Yevick and hypernetted-chain integral equations. It is found that the rational-function approximation generally predicts a more accurate radial distribution function than the Percus-Yevick theory and is comparable or even superior to the hypernetted-chain theory. This superiority over both integral equation theories is lost, however, at high densities, especially as the widths of the wells and/or the barriers increase.Comment: 10 pages, 11 figures; v2: Old Fig. 1 removed, new text on the correlation length, 7 new references added, plus other minor change

Recommendations for the Clinical Approach to Immune Thrombocytopenia: Spanish ITP Working Group (GEPTI)

© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).Primary immune thrombocytopenia (ITP) is a complex autoimmune disease whose hallmark is a deregulation of cellular and humoral immunity leading to increased destruction and reduced production of platelets. The heterogeneity of presentation and clinical course hampers personalized approaches for diagnosis and management. In 2021, the Spanish ITP Group (GEPTI) of the Spanish Society of Hematology and Hemotherapy (SEHH) updated a consensus document that had been launched in 2011. The updated guidelines have been the reference for the diagnosis and management of primary ITP in Spain ever since. Nevertheless, the emergence of new tools and strategies makes it advisable to review them again. For this reason, we have updated the main recommendations appropriately. Our aim is to provide a practical tool to facilitate the integral management of all aspects of primary ITP management.Peer reviewe

Medición de los Equilibrios Líquido - Líquido y Densidades en la Saturación y en Fase Homogénea del Sistema Etano + 1-Propanol Mediante la Técnica de Densimetría de Tubo Vibrante

Tesis (Maestría en Ciencias en Ingeniería Química), Instituto Politécnico Nacional, SEPI, ESIQIE, 2004, 1 archivo PDF, (186 páginas). tesis.ipn.m

Masculinidades de seminaristas: la masculinidad religiosa y la masculinidad clerical

Este estudio aborda la formación sacerdotal y la manera en que diversos factores se entretejen y dan como resultado dos masculinidades en relación con el entorno rural del Municipio de Texcoco, Estado de México. La metodología consistió en la aplicación de diversos instrumentos de los cuales se obtuvieron datos cuantitativos y cualitativos. Con base en lo anterior se propusieron dos conceptos de masculinidad que son: 1) masculinidad religiosa, características de los varones que eligen el sacerdocio; y 2) masculinidad clerical, características de los varones que se encuentran en la formación sacerdotal

Comparison and Analysis of Diffusion Models: Growth Kinetics of Diiron Boride Layers on ASTM A283 Steel

Hard-coated surfacing of a few micrometers is widely applied to increase the efficiency of tools, e.g., for cutting, forming, and casting applications. Therefore, the base thermodiffusion surface treatment is a practical solution to these issues by hardening surface layers with interstitial elements such as carbon, nitrogen, and boron. In particular, within this study, the growth kinetics of an iron boride layer on ASTM 283 steel were investigated with two diffusion models of the powder-pack boriding technique in the temperature range of 1123–1273 K with different treatment periods. The first model, called the steady-state diffusion model, used the modified version of the mass balance equations at the Fe2B/substrate growth interface, the parabolic growth law, and the solution of Fick’s second law without time dependence. At the same time, the second diffusion model was based on Goodman’s method, also called the integral heat balance method. Afterward, the diffusion coefficient of boron in the Fe2B phase was calculated by fitting the experimental data to the models. Nevertheless, the estimated value for the activation energy of ASTM A238 steel in both diffusion models was coincident (168.2 kJ∙mol−1). A mathematical analysis was implemented by means of a power series (Taylor series) to explain this similarity. The SEM examinations showed a solid tendency to saw-tooth morphology at the growth interface with the formation of the Fe2B layer, whose presence was verified by XRD analysis. The tribological characterizations, including the tests of Rockwell-C indentation, pin-on-disc, and Vickers hardness test method, were used to analyze the antiwear features of the Fe2B layers. Finally, this value of energy was compared to the literature for its experimental validation

COVID-19 vaccines and autoimmune hematologic disorders

Worldwide vaccination against SARS-CoV-2 has allowed the detection of hematologic autoimmune complications. Adverse events (AEs) of this nature had been previously observed in association with other vaccines. The underlying mechanisms are not totally understood, although mimicry between viral and self-antigens plays a relevant role. It is important to remark that, although the incidence of these AEs is extremely low, their evolution may lead to life-threatening scenarios if treatment is not readily initiated. Hematologic autoimmune AEs have been associated with both mRNA and adenoviral vector-based SARS-CoV-2 vaccines. The main reported entities are secondary immune thrombocytopenia, immune thrombotic thrombocytopenic purpura, autoimmune hemolytic anemia, Evans syndrome, and a newly described disorder, so-called vaccine-induced immune thrombotic thrombocytopenia (VITT). The hallmark of VITT is the presence of anti-platelet factor 4 autoantibodies able to trigger platelet activation. Patients with VITT present with thrombocytopenia and may develop thrombosis in unusual locations such as cerebral beds. The management of hematologic autoimmune AEs does not differ significantly from that of these disorders in a non-vaccine context, thus addressing autoantibody production and bleeding/thromboembolic risk. This means that clinicians must be aware of their distinctive signs in order to diagnose them and initiate treatment as soon as possible

COVID-19 vaccines and autoimmune hematologic disorders

Worldwide vaccination against SARS-CoV-2 has allowed the detection of hematologic autoimmune complications. Adverse events (AEs) of this nature had been previously observed in association with other vaccines. The underlying mechanisms are not totally understood, although mimicry between viral and self-antigens plays a relevant role. It is important to remark that, although the incidence of these AEs is extremely low, their evolution may lead to life-threatening scenarios if treatment is not readily initiated. Hematologic autoimmune AEs have been associated with both mRNA and adenoviral vector-based SARS-CoV-2 vaccines. The main reported entities are secondary immune thrombocytopenia, immune thrombotic thrombocytopenic purpura, autoimmune hemolytic anemia, Evans syndrome, and a newly described disorder, so-called vaccine-induced immune thrombotic thrombocytopenia (VITT). The hallmark of VITT is the presence of anti-platelet factor 4 autoantibodies able to trigger platelet activation. Patients with VITT present with thrombocytopenia and may develop thrombosis in unusual locations such as cerebral beds. The management of hematologic autoimmune AEs does not differ significantly from that of these disorders in a non-vaccine context, thus addressing autoantibody production and bleeding/thromboembolic risk. This means that clinicians must be aware of their distinctive signs in order to diagnose them and initiate treatment as soon as possible

Recommendations on the management of patients with immune thrombocytopenia (ITP) in the context of SARS-CoV-2 infection and vaccination: Consensus guidelines from a Spanish ITP expert group

Primary immune thrombocytopenia (ITP) is an acquired autoimmune disease with highly variable presentation, characteristics, and clinical course. Thrombocytopenia is a common complication of many viral infections, including SARS-CoV-2. In addition, both de novo ITP and exacerbation of ITP after vaccination against SARS-CoV-2 have been reported. Patients infected with SARS-CoV-2 develop a prothrombotic coagulopathy called COVID-19-associated coagulopathy (CAC). In addition, autoimmune hematological disorders secondary to SARS-CoV-2 infection, mainly ITP and autoimmune hemolytic anemia (AIHA), have been described. Furthermore, SARS-CoV-2 infection has been associated with exacerbation of autoimmune processes, including ITP. In fact, there is evidence of a high relapse rate in patients with preexisting ITP and COVID-19. As for vaccination against SARS-CoV-2, hematological adverse events (HAE) are practically anecdotal. The most common HAE is thrombocytopenia-associated thrombosis syndrome (TTS) linked to vectored virus vaccines. Other HAEs are very rare, but should be considered in patients with previous complement activation disease or autoimmunity. In patients with ITP who are vaccinated against SARS-CoV-2, the main complication is exacerbation of ITP and the bleeding that may result. In fact, this complication occurs in 12% of patients, with splenectomized and refractory patients with more than five lines of previous treatment and platelet counts below 50 × 109/L being the most vulnerable. We conclude that, in general, there is no greater risk of severe SARS-CoV-2 infection in ITP patients than in the general population. Furthermore, no changes are advised in patients with stable ITP, the use of immunosuppressants is discouraged unless there is no other therapeutic option, and patients with ITP are not contraindicated for vaccination against COVID-19